Wednesday, May 20, 2026

3:40 PM - 4:25 PM

---

Overview

Sponsored by: RMIT

---

Details

Australia’s medtech sector is rich in innovation, yet too many promising devices stall between prototype and patient impact. The challenge is not a lack of ideas, but fragmented translation that creates risk, delay, and value loss, where design, clinical evidence, regulation, reimbursement, and market access are treated as sequential hurdles rather than an integrated system. This session explores a different operating model: embedding user-centred design, advanced prototyping, clinical and health-economic evidence, regulatory readiness, and access strategy from day one. Chaired by Distinguished Professor Madhu Bhaskaran, Director of the Discovery to Device (D2D) Prototyping Facility at RMIT University, the panel brings together leaders from human-factors design, clinical translation, patient advocacy, and global market access to examine what genuinely de-risks device development in Australia. Drawing on real-world experiences, the discussion will surface where translation fails and shows how integrated infrastructure and cross-sector collaboration can shorten time to evidence, reimbursement, and adoption, helping innovators move from concept to care faster and with greater confidence. Session sponsor:

---

Speaker